Journal article
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma
Hematological oncology, Vol.36(5), pp.749-756
12/2018
DOI: 10.1002/hon.2522
PMCID: PMC6402794
PMID: 29862550
Abstract
Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overall survival (OS). QOL was measured with the Functional Assessment of Cancer Treatment-General (FACT-G), which measures 4 domains: physical, social/family, emotional, and functional well-being (WB); a single item Linear Analogue Self-Assessment (LASA) measuring overall QOL; and a spiritual WB LASA. From 9/2002 to 12/2009, 701 patients with aggressive lymphoma who completed baseline QOL questionnaires were enrolled. At a median follow-up of 71 months (range 6-128), 316 patients (45%) had an event and 228 patients (33%) died. All baseline QOL measures but emotional WB were significantly associated with OS (all P < 0.04); of which all but LASA spiritual remained significant after adjusting for IPI and NHL subtype. The strongest associations were with total FACT-G (adjusted HR = 0.86, 95% CI: 0.79-0.94, P = 0.00062) and functional WB (adjusted HR = 0.88, 95% CI: 0.83-0.93, P < .0001). QOL LASA was associated with OS (adjusted HR = 0.92, 95% CI: 0.87-0.97, P = 0.0041). Patients with clinically deficient QOL (overall QOL ≤50) had a median OS of 92 months compared with 121 months for patients with QOL >50 (P = 0.0004). In this large sample of patients with aggressive lymphoma, we found that baseline QOL is independently predictive of OS. QOL should be assessed as a prognostic factor in patients with aggressive lymphoma.
Details
- Title: Subtitle
- Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma
- Creators
- Carrie A Thompson - Mayo ClinicKathleen J Yost - Mayo Clinic in FloridaMatthew J Maurer - Mayo ClinicCristine Allmer - Mayo Clinic in FloridaUmar Farooq - University of IowaThomas M Habermann - Mayo ClinicDavid J Inwards - Department of Internal Medicine/Division of Hematology, Mayo Clinic, Rochester, MN, USAWilliam R Macon - Mayo ClinicBrian K Link - University of IowaAllison C Rosenthal - Mayo Clinic in FloridaJames R Cerhan - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Hematological oncology, Vol.36(5), pp.749-756
- DOI
- 10.1002/hon.2522
- PMID
- 29862550
- PMCID
- PMC6402794
- ISSN
- 0278-0232
- eISSN
- 1099-1069
- Grant note
- Henry J. Predolin Foundation Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery P50 CA97274 / NIH HHS P30 CA086862 / NCI NIH HHS Arnold and Kit Palmer Benefactor Award P50 CA097274 / NCI NIH HHS
- Language
- English
- Date published
- 12/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984359950202771
Metrics
13 Record Views